Novo Nordisk’s investor relations manager David Heiberg Landsted confirmed the current priority of the drugmaker is on ramping up manufacturing. “Just this year alone, the expectation is that ...

Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm ...

Dec 26, 2024 by Adam Spatacco Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear. Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, ...

Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $85 per share, more than 40% below its peak level of over $145 seen in June of this year. In contrast, its closest peer, Eli Lilly stock (NYSE ...

LONDON/COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...